List of Figures
Figure 1-1: Evolutionary Trails of Cancer Immunotherapy
Figure 1-2: Layout of Necessity of Cancer Immunotherapies for Cancer Treatment
Figure 1-3: Potential Benefits of Cancer Immunotherapies

Figure 2-1: Classification of Cancer Immunotherapies
Figure 2-2: Categorization of Specific Immunotherapy
Figure 2-3: Non-Specific Cancer Immunotherapies

Figure 3-1: Favorable Cancer Immunotherapy Market Parameters
Figure 3-2: Cancer Immunotherapy Commercialization Challenges

Figure 4-1: Categorization & Function of Cancer Vaccines
Figure 4-2: Mechanism of the Cancer Vaccine towards Tumor Eradication
Figure 4-3: Global - Cancer Vaccines Market (US$ Billion), 2018-2026

Figure 5-1: Process of Manufacturing of Monoclonal Antibody
Figure 5-2: Principles of Monoclonal Antibodies
Figure 5-3: Evolution of Monoclonal Antibody over Generations
Figure 5-4: Classification of Monoclonal Antibodies
Figure 5-5: Representation of Mechanism of Alemtuzumab
Figure 5-6: Representation of Mechanism of Ibritumomab Tiuxetan
Figure 5-7: Representation of Mechanism of Blinatumomab
Figure 5-8: Global - Market for Cancer Monoclonal Antibodies (US$ Billion), 2018-2026

Figure 6-1: Benefit of Adoptive Cell Transfer Immunotherapy
Figure 6-2: Systematic Representation of Adoptive T-Cell Therapies
Figure 6-3: Three Adoptive Cell Transfer Strategies for Cancer Immunotherapy
Figure 6-4: Tumor-Infiltrating Lymphocytes in Adoptive Cell Transfer
Figure 6-5: Mechanism of CAR Modified T-Cells
Figure 6-6: Genetically Engineered TCR for Cancer Immunotherapy
Figure 6-7: Global - Predictive Market of CAR T-Cell Therapeutics (US$ Million), 2018-2026

Figure 7-1: Benefits of Immune Checkpoint Inhibitors
Figure 7-2: Implication of Adaptive Immune Resistance Mechanism
Figure 7-3: Mechanism of Ipilimumab
Figure 7-4: Layout of Mechanism of Nivolumab
Figure 7-5: Mechanism of Pembrolizumab
Figure 7-6: Global - Immune Check Point Inhibitors Market (US$ Billion), 2018-2026

Figure 8-1: Functions of Immunomodulators
Figure 8-2: Benefits of Immunomodulators
Figure 8-3: Layout of the Challenges of Immunomodulators
Figure 8-4: Properties of Thalidomide
Figure 8-5: Mechanism of Lenalidomide In Vivo
Figure 8-6: Mechanism of Lenalidomide in Vitro
Figure 8-7: Mechanism of Pomalidomide
Figure 8-8: Global - Immunomodulators Market for All Indications (US$ Billion), 2018-2026

Figure 9-1: Demonstration of Categorization of Oncolytic Viruses
Figure 9-2: Potential Advantages of Oncolytic Viruses over Conventional Therapies
Figure 9-3: Global - Predicted Market Share of Oncolytic Viral Therapies (US$ Million), 2018-2026

Figure 10-1: Layout of Functions Performed by Cytokine
Figure 10-2: Benefits of Cytokines in Cancer Immunotherapy
Figure 10-3: Classification of Cytokine Receptor Family
Figure 10-4: Percentage Share of the Cancer Immunotherapies by the Technology

Figure 11-1: Layout of Functions of Interferon
Figure 11-2: Classification of Interferons on the Basis of Types of Genes
Figure 11-3: General Mechanism of Interferons
Figure 11-4: Mechanism of Interferon Alfa-n3
Figure 11-5: Aspects of Peginterferon Alfa-2a
Figure 11-6: Applications of Interferon Beta 1a
Figure 11-7: Potentials of Interferon Alfa-2b

Figure 12-1: Functions of Interleukin
Figure 12-2: Potentials of Interleukins in Cancer Immunotherapy
Figure 12-3: Clinical Potentials of Proleukin
Figure 12-4: Clinical Potentials of Denileukin Diftitox

Figure 13-1: Potential Applications of GM-CSF
Figure 13-2: Mechanism of Sargramostim

Figure 14-1: Global - Cancer Immunotherapeutic Market (US$ Billion), 2018-2026
Figure 14-2: Expected Cancer Treatment Cost (US$ Billion), 2016-2022
Figure 14-3: Comparative Analysis of Available Cancer Treatments
Figure 14-4: Major Approved Immunotherapeutic Drugs
Figure 14-5: Annual per Patient Drug Expenditure of Immunotherapy

Figure 15-1: Global - Cancer Vaccine Clinical Pipeline by Phase (%), 2020 - 2026
Figure 15-2: Global - Cancer Vaccine Clinical Pipeline by Phase (Number), 2020 -2026
Figure 15-3: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2020 -2026
Figure 15-4: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2020 -2026
Figure 15-5: Global - Cancer Cell Therapies Clinical Pipeline by Phase (%), 2020 -2026
Figure 15-6: Global - Cancer Cell Therapies Clinical Pipeline by Phase (Number), 2020 -2026
Figure 15-7: Global - Cancer Immunomodulators Clinical Pipeline by Phase (%), 2020 - 2026
Figure 15-8: Global - Cancer Immunomodulators Clinical Pipeline By Phase (Number), 2020 - 2026
Figure 15-9: Global - Cancer Immunotherapy Clinical Pipeline by Phase (Number), 2020 -2026
Figure 15-10: Global - Cancer Immunotherapy Clinical Pipeline by Company (Number), 2020 -2026
Figure 15-11: Global - Cancer Immunotherapy Clinical Pipeline by Target (Number), 2020 -2026
Figure 15-12: Global - Cancer Immunotherapy Clinical Pipeline by Patient Segment (Number), 2020 -2026

Figure 16-1: Keytruda – Patent Expiration Year by Region
Figure 16-2: Keytruda – Price for 4ml & 8ml Supply & Price per ml of Intravenous Injection (US$), January’2020
Figure 16-3: Keytruda – Duration of Single Treatment Cycle & Full Treatment of Melanoma & Other Cancers (Weeks), January’2020
Figure 16-4: Keytruda – Cost of Single and Full Treatment using Powder of Injection (US$), January’2020
Figure 16-5: Keytruda - Cost of Single and Full Treatment using Solution of Injection (US$), January’2020
Figure 16-6: Keytruda – Annual Sales Value (US$ Billion), 2016, 2017 & 2018
Figure 16-7: Keytruda – Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
Figure 16-8: Yervoy – US & Europe Exclusivity Expiration Year
Figure 16-9: Yervoy - Price for 10ml Supply & Price per ml 5mg/ml Intravenous Injection (US$), January’2020
Figure 16-10: Yervoy – Price for 40ml Supply & Price per ml 5mg/ml Intravenous Injection (US$), January’2020
Figure 16-11: Yervoy – Duration of Single Treatment Cycle & Full Treatment of Metastatic Melanoma (Weeks), January’2020
Figure 16-12: Yervoy – Average Cost of Single Treatment Cycle & Full Treatment of Metastatic Melanoma (US$), January’2020
Figure 16-13: Yervoy – Average Cost of Single Treatment Cycle, Initial Year & Remaining Years for Management of Metastatic Melanoma (US$), January’2020
Figure 16-14: Yervoy – Duration of Single Treatment Cycle & Full Treatment in Combinational Therapy (Weeks), January’2020
Figure 16-15: Yervoy – Average Cost of Single Treatment Cycle & Full Treatment in Combinational Therapy (US$), January’2020
Figure 16-16: Yervoy – Annual Sales Value (US$ Billion), 2016-2018
Figure 16-17: Yervoy – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 16-18: US - Yervoy Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 16-19: Yervoy – US v/s Rest of World Sales Share (%), Q1-Q3, 2019
Figure 16-20: Opdivo - Patent Expiration Year by Region
Figure 16-21: Opdivo - Price for 4ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$), January’2020
Figure 16-22: Opdivo - Price for 10 ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$), January’2020
Figure 16-23: Opdivo - Price for 20 ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$), January’2020
Figure 16-24: Opdivo Monotherapy Therapy - Single Treatment Cycle & Full Treatment Average Cost (US$), January’2020
Figure 16-25: Opdivo Combination – Dose for Management of Melanoma & Renal Cell Carcinoma (mg/3 Weeks)), January’2020
Figure 16-26: Opdivo – Annual Sales Value (US$ Billion), 2016 - 2018
Figure 16-27: Opdivo – Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
Figure 16-28: US - Opdivo – Quarterly Sales Value (US$ Billion), Q1-Q3, 2019
Figure 16-29: Opdivo – 9 Month Sales Share of US & Rest of World (%), Q1-Q3, 2019
Figure 16-30: Tecentriq - Price for 14ml Supply & Price per ml of 840mg/14ml Intravenous Injection (US$), January’2020
Figure 16-31: Tecentriq - Price for 20ml Supply & Price per ml of 1200mg/20ml Intravenous Injection (US$), January’2020
Figure 16-32: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 840mg/2 Week Dose (US$), January’2020
Figure 16-33: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1200mg/3 Week Dose (US$), January’2020
Figure 16-34: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1680mg/4 Week Dose (US$), January’2020
Figure 16-35: Tecentriq – Annual Sales Value (US$/CHF Million), 2017 & 2018
Figure 16-36: Tecentriq – Quarterly Sales Value (US$ Million), Q1-Q3, 2019
Figure 16-37: Tecentriq – Quarterly Sales Value (US$ Million), 2018
Figure 16-38: Tecentriq – Sales Value of US v/s ROW (US$ Billion), Q1-Q3, 2019
Figure 16-39: Tecentriq – 9 Month Sales Share by Region (%), Q1-Q3, 2019
Figure 16-40: Bavencio - Price for 10ml Supply & Price per ml of 20mg/ml Intravenous Injection (US$), January’2020
Figure 16-41: Bavencio - Average Cost of Single Treatment Cycle & Annual Treatment (US$), January’2020
Figure 16-42: Bavencio – Annual Sales Value (US$/EUR Million), 2017 & 2018
Figure 16-43: Bavencio – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 16-44: Imfinzi – FDA Approval & Patent Expiration Year
Figure 16-45: Imfinzi – Price for a Supply of 2.4ml & Price per ml of Solution for Injection (US$), January’2020
Figure 16-46: Imfinzi – Price for a Supply of 10 ml & Price per ml of Solution for Injection (US$), January’2020
Figure 16-47: Imfinzi - Average Cost of Single Treatment Cycle & Full Treatment of NSCLC (US$), January’2020
Figure 16-48: Imfinzi – Annual Sales Value (US$ Million), 2017 & 2018
Figure 16-49: Imfinzi – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 16-50: Libtayo – Price for a Supply of 7ml & Price per ml of Solution for Injection (US$), January’2020
Figure 16-51: Libtayo – Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January’2020
Figure 16-52: Libtayo – Quarterly Sales Value (US$ Million), Q1-Q3, 2019
Figure 16-53: US - Libtayo Quarterly Sales Value (US$ Million), Q1-Q3, 2019
Figure 16-54: Libtayo – 9 Month Sales Share – US v/s Rest of World (%), Q1-Q3, 2019
Figure 16-55: Libtayo – 9 Month Sales of US v/s Rest of World (US$ Million), Q1-Q3, 2019

Figure 17-1: Herceptin – Approval Year by Cancer Type
Figure 17-2: Herceptin – Price for a Supply of 10 and Price for Single 150mg Powder for Injection (US$), January’2020
Figure 17-3: Herceptin – Initial & Maintenance Dose for Breast Cancer Treatment (mg/kg), January’2020
Figure 17-4: Herceptin – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Breast Cancer (US$), January’2020
Figure 17-5: Herceptin – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg), January’2020
Figure 17-6: Herceptin – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US$), January’2020
Figure 17-7: Herceptin – Annual Sales Value (US$/CHF Billion), 2017 & 2018
Figure 17-8: Herceptin – Quarterly Sales Value (US$/CHF Billion), Q1-Q4, 2018
Figure 17-9: Herceptin – Quarterly Sales Value (US$/CHF Billion), Q1-Q3, 2019
Figure 17-10: US - Herceptin – Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
Figure 17-11: Herceptin – Sales Value – US v/s ROW (US$ Billion), 2018
Figure 17-12: Herceptin –Sales Share by Region (%), 2018
Figure 17-13: Avastin – Price for a Supply of 10 & Price for Single 4ml Solution for Injection (US$), January’2020
Figure 17-14: Avastin – Price for a Supply of 10 & Price for Single 16ml Solution for Injection (US$), January’2020
Figure 17-15: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$), January’2020
Figure 17-16: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), January’2020
Figure 17-17: Avastin – Duration of Treatment of Recurrent Glioblastoma & Renal Cell Carcinoma as Combinational & Monotherapy (Weeks), January’2020
Figure 17-18: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), January’2020
Figure 17-19: Avastin – Annual Sales Value (US$/CHF Billion), 2017 & 2018
Figure 17-20: Avastin – Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
Figure 17-21: US - Avastin – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 17-22: Avastin – 9 Month Sales Share by Region (US$ Billion), Q1-Q3, 2019
Figure 17-23: Avastin – 9 Month Sales Share of US & Rest of World (%), Q1-Q3, 2019
Figure 17-24: Rituxan – Price for a Supply of 10 ml & Price per ml of Solution for Injection (US$), January’2020
Figure 17-25: Rituxan – Price for a Supply of 50 ml & Price per ml of Solution for Injection (US$), January’2020
Figure 17-26: Rituxan – Price for a Supply of 100 ml & Price per ml of Solution for Injection (US$), January’2020
Figure 17-27: Rituxan – Average Minimum & Maximum Cost for Refractory CD20+ B-Cell NHL (US$), January’2020
Figure 17-28: Rituxan – Average Cost for Single Dose & Cost of Full Maintenance Phase for Non-Progressing CD20+ B-Cell NHL (US$), January’2020
Figure 17-29: Rituxan – Annual Sales Value (US$/CHF Billion), 2017 & 2018
Figure 17-30: Rituxan – Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
Figure 17-31: US - Rituxan – Quarterly Sales Value (US$ Billion), Q1-Q3, 2019
Figure 17-32: Avastin – 9 Month Sales Share of US & Rest of World (%), Q1-Q3, 2019
Figure 17-33: Rituxan – 9 Month Sales Share by Region (CHF/US$ Billion)), Q1-Q3, 2019
Figure 17-34: Rituxan – 9 Month Sales Share by Region (%), Q1-Q3, 2019
Figure 17-35: Erbitux - Approval Year by Cancer Type
Figure 17-36: Erbitux - Price for a Supply of 50 ml & Price per ml of Intravenous Solution (US$), January’2020
Figure 17-37: Erbitux - Price for a Supply of 100 ml & Price per ml of Intravenous Solution (US$), January’2020
Figure 17-38: Erbitux – Initial & Maintenance Dose for Colorectal, Head & Neck Cancer Treatment (mg/ m2), January’2020
Figure 17-39: Erbitux – Average Cost of Initial Dose, Maintenance Dose & Cost of Annual Treatment (US$), January’2020
Figure 17-40: Erbitux – Annual Sales Value (US$ Million), 2016 - 2018
Figure 17-41: US - Erbitux Sales Value (US$ Million), 2017 & 2018
Figure 17-42: Erbitux - Sales Share US v/s Rest of World (%), 2018
Figure 17-43: Erbitux – Quarterly Sales Value (US$ Million), Q1-Q3, 2017 & 2018
Figure 17-44: Vectibix - FDA Approval & Patent Expiration Year
Figure 17-45: Vectibix – Price for a Supply of 5 ml & Price per ml of Intravenous Solution (US$), January’2020
Figure 17-46: Vectibix – Price for a Supply of 20 ml & Price per ml of Intravenous Solution (US$), January’2020
Figure 17-47: Vectibix – Cost of Single Treatment Cycle & Annual Treatment Cost for Colorectal Cancer (US$), January’2020
Figure 17-48: Vectibix – Annual Sales Value (US$ Million), 2015 - 2018
Figure 17-49: Vectibix - Sales Share US v/s Rest of World (%), 2018
Figure 17-50: Vectibix – Quarterly Sales Value (US$ Million), Q1 – Q3, 2018 & 2019
Figure 17-51: Vectibix – 9 Month Sales Share US v/s Rest of World (%), Q1 – Q3, 2019
Figure 17-52: Arzerra – Price for a Supply of 15 ml, 5 ml and Price per ml of Intravenous Solution (US$), January’2020
Figure 17-53: Arzerra – Price for a Supply of 50 ml & Price per ml of Intravenous Solution (US$), January’2020
Figure 17-54: Arzerra – Initial & Maintenance Dose for Previously Untreated CLL (mg), January’2020
Figure 17-55: Arzerra – Minimum & Maximum Treatment Duration for Previously Untreated CLL (Weeks), January’2020
Figure 17-56: Arzerra – Minimum & Maximum Treatment Cost for Previously Untreated CLL (US$), January’2020
Figure 17-57: Arzerra – Initial & Maintenance Dose for Relapsed CLL (mg), January’2020
Figure 17-58: Arzerra – Minimum & Maximum Treatment Cost for Relapsed CLL (US$), January’2020
Figure 17-59: Arzerra – Initial & Maintenance Dose for Refractory CLL (mg), January’2020
Figure 17-60: Arzerra – Treatment Duration for Refractory CLL (Weeks), January’2020
Figure 17-61: Arzerra – Minimum & Maximum Treatment Cost for Refractory CLL (US$), January’2020
Figure 17-62: Gazyva – Approval Year by Cancer Type
Figure 17-63: Gazyva – Price for 40ml Supply & Price per ml of Intravenous Solution (US$), January’2020
Figure 17-64: Gazyva – Recommended Dosing Schedule for Initial Treatment Cycle of CLL (mg), January’2020
Figure 17-65: Gazyva – Duration of Single Treatment Cycle & Full Treatment of CLL (Week), January’2020
Figure 17-66: Gazyva – Cost of Initial & Subsequent Treatment Cycle & Full Treatment Cost of CLL (US$), January’2020
Figure 17-67: Gazyva – Minimum & Maximum Duration for Follicular Lymphoma Treatment (Week), January’2020
Figure 17-68: Gazyva – Minimum & Maximum Treatment Cost of Follicular Lymphoma (US$), January’2020
Figure 17-69: Gazyva – Duration of Single Treatment Cycle & Full Treatment Using Monotherapy (Months), January’2020
Figure 17-70: Gazyva – Cost of Single Treatment Cycle & Full Treatment using Monotherapy (US$), January’2020
Figure 17-71: Gazyva – Annual Sales Value (US$/CHF Million), 2016 - 2018
Figure 17-72: Gazyva – Quarterly Sales Value (US$/CHF Million), 2018
Figure 17-73: Gazyva – Quarterly Sales Value (US$/CHF Million), Q1-Q3, 2019
Figure 17-74: US - Gazyva – Quarterly Sales Value (US$ Million), Q1-Q3, 2019
Figure 17-75: Gazyva – 9 Month Sales Share by Region (CHF/US$ Million), Q1-Q3, 2019
Figure 17-76: Gazyva – 9 Month Sales Share by Region (%), Q1-Q3, 2019
Figure 17-77: Perjeta - Approval Year by Cancer Type
Figure 17-78: Perjeta – Patent Expiration Year – US & Europe
Figure 17-79: Perjeta – Price for a Supply of 10 ml and Price per ml of Intravenous Solution (US$), January’2020
Figure 17-80: Perjeta – Initial & Maintenance Dose for Breast Cancer Treatment (mg/ 3 weeks), January’2020
Figure 17-81: Perjeta – Minimum & Maximum Treatment Cost for Breast Cancer (US$), January’2020
Figure 17-82: Perjeta – Minimum & Maximum Treatment Cost of Neoadjuvant Breast Cancer Treatment (US$), January’2020
Figure 17-83: Perjeta – Annual Sales Value (US$/CHF Billion), 2016 - 2018
Figure 17-84: Perjeta – Quarterly Sales Value (US$/CHF Million), 2018
Figure 17-85: Perjeta – Quarterly Sales Value (US$/CHF Million), Q1-Q3, 2019
Figure 17-86: US - Perjeta – Quarterly Sales Value (US$ Million), Q1-Q3, 2019
Figure 17-87: Perjeta – Sales Value by Region (US$/CHF Million), Q1 – Q3, 2019
Figure 17-88: Perjeta – Sales Value by Region, Q1 – Q3, 2019

Figure 18-1: Blincyto - Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL, January’2020
Figure 18-2: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days) , January’2020
Figure 18-3: Blincyto - Cost of Single Cycle & Full Treatment Cost of MRD+ B-cell precursor ALL (US$), January’2020
Figure 18-4: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, January’2020
Figure 18-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), January’2020
Figure 18-6: Blincyto - Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), January’2020
Figure 18-7: Blincyto - Cost of Different Treatment Phases & Full Treatment Cost for Relapsed B-Cell Precursor ALL (US$), January’2020
Figure 18-8: Blincyto - Sales Value (US$ Million), 2015 - 2018
Figure 18-9: US - Blincyto Sales Value (US$ Million), 2016 - 2018
Figure 18-10: Blincyto - Quarterly Sales Value (US$ Million), 2018
Figure 18-11: Blincyto - US v/s Rest of World Share in Sales Value (%), 2018
Figure 18-12: Blincyto - Quarterly Sales Value (US$ Million), Q1 – Q3, 2018 & 2019
Figure 18-13: Blincyto - US & Rest of World Sales Value (US$ Million), Q1 - Q3, 2019
Figure 18-14: Blincyto - US v/s ROW Share in 9 Month Sales Value (%), 2019

Figure 19-1: Gardasil & Gardasil 9 – FDA Approval Year
Figure 19-2: Gardasil – Patent Expiration Year of US & Europe
Figure 19-3: Gardasil 9 – US & Europe Patent Expiration Year
Figure 19-4: Gardasil – Price for 0.5ml Supply & Price per ml of Intravenous Suspension (US$), January’2020
Figure 19-5: Gardasil – Price for 3ml Supply & Price per ml of Intravenous Suspension (US$), January’2020
Figure 19-6: Gardasil – Price for 5ml Supply & Price per ml of Intravenous Suspension (US$), January’2020
Figure 19-7: Gardasil 9 – Price for 5ml Supply & Price per ml of Intravenous Suspension (US$), January’2020
Figure 19-8: Gardasil – Cost of Single Dose & Cost of Full Course (US$), January’2020
Figure 19-9: Gardasil 9 – Cost of Single Dose & Cost of Full Course (US$), January’2020
Figure 19-10: Gardasil & Gardasil 9 – Annual Sales Value (US$ Million), 2016, 2017 & 2018
Figure 19-11: Gardasil and Gardasil 9 – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 19-12: Cervarix – US & Europe Patent Expiration Year
Figure 19-13: Cervarix – Cost of Single Dose & Cost of Full Course (US$/GBP Million), January’2020
Figure 19-14: Cervarix – Annual Sales Value (US$/GBP Million), 2016 - 2018
Figure 19-15: Cervarix - Sales Share Europe v/s Rest of World (%), 2018
Figure 19-16: Cervarix – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 19-17: Cervarix - Europe v/s Rest of World Sales Share (%), Q1-Q3, 2019
Figure 19-18: Provenge – Price for 250 ml Supply & Price per ml of Intravenous Suspension (US$), January’2020
Figure 19-19: Provenge – Cost of Single Treatment Cycle & Cost of Full Treatment (US$), January’2020
Figure 19-20: Vaxira – Cost for Single Injection & Single Dose (US$), January’2020
Figure 19-21: Vaxira – Number of Doses in Induction & Maintenance Phase, January’2020
Figure 19-22: Vaxira – Dose Interval in Induction & Maintenance Phase (Week), January’2020
Figure 19-23: Vaxira – Duration of Induction & Maintenance Phase (Weeks), January’2020
Figure 19-24: Vaxira – Cost of Induction & Maintenance Phase (US$), January’2020
Figure 19-25: CreaVax-RCC – Duration of Single Cycle & Full Treatment (Weeks), January’2020

Figure 20-1: Proleukin – Duration of Treatment by Phases (Hours), January’2020
Figure 20-2: Proleukin - Cost of Single Dose, Single Treatment Cycle & Full Treatment (US$), January’2020
Figure 20-3: Proleukin – Number of Doses for Metastatic Renal Cell Carcinoma & Melanoma, January’2020
Figure 20-4: Proleukin – Average Cost For Treatment of Metastatic RCC & Melanoma, January’2020
Figure 20-5: Intron A – Price for a Supply of 10, 18 & 50 Million IU Powder for Injection (US$), January’2020
Figure 20-6: Intron A – Price for a Supply of 6 & 10 Million IU/ml Intravenous Solution (US$), January’2020
Figure 20-7: Intron A – Average Cost of Single Treatment Cycle for Hairy Cell Leukemia using Powder & Solution for Injection (US$), January’2020
Figure 20-8: Intron A – Average Cost of Full Treatment for Course Hairy Cell Leukemia using Powder & Solution for Injection (US$), January’2020
Figure 20-9: Intron A – Dose for Induction & Maintenance Phase for Malignant Melanoma Treatment (Million IU/m2), January’2020
Figure 20-10: Intron A – Duration of Induction & Maintenance Phase for Malignant Melanoma Treatment (Weeks), January’2020
Figure 20-11: Intron A – Duration of Single Treatment Cycle & Full Treatment of Follicular Lymphoma (Weeks), January’2020
Figure 20-12: PegIntron - Patent Expiration Year by Region
Figure 20-13: PegIntron – Price for 4 Powder Supply & Price Per Unit of 120mg Powder for Injection (US$), January’2020
Figure 20-14: PegIntron Monotherapy – Dose by Weight of Patient (mcg), January’2020
Figure 20-15: PegIntron Monotherapy – Reduced Dose by Weight of Patient (mcg), January’2020
Figure 20-16: Pegintron Combination – Duration of Treatment by Genotype (Weeks), January’2020
Figure 20-17: Sylatron – Price for 4 Powder Supply & Price per Unit of 120mg Powder for Injection (US$), January’2020
Figure 20-18: Sylatron – Initial & Maintenance Dose (mcg/Kg/Week), January’2020
Figure 20-19: Sylatron – Duration of Initial Phase, Maintenance Phase & Full Treatment (Weeks), January’2020
Figure 20-20: Sylatron - Average Cost of Single Initial Dose & Full Initial Phase (US$), January’2020
Figure 20-21: Sylatron - Average Cost of Single Maintenence Dose, Annual Maintenance Cost & Full Maintenance Phase (US$), January’2020
Figure 20-22: Betaseron – Price for 14 Powder Supply & Price per Unit of 0.3mg Powder for Injection (US$), January’2020
Figure 20-23: Betaseron – Dose Incrimination Pattern (mg/48 hours), January’2020
Figure 20-24: Betaseron – Sales Value (US$/EUR Million), 2017 & 2018
Figure 20-25: Betaseron – US v/s ROW Sales Value (%), 2018
Figure 20-26: Betaseron – Quarterly Sales Value (US$/EUR Million), 2018
Figure 20-27: Betaseron – Quarterly Sales Value (US$/EUR Million), Q1 – Q3, 2019
Figure 20-28: Actimmune - FDA Approval & Patent Expiration Year
Figure 20-29: Actimmune – Price for 6ml Supply, 1 ml & price for Single Vial of 0.5ml Subcutaneous Solution (US$), January’ 2020
Figure 20-30: Actimmune – Average Cost of Single Dose & Single Treatment Cycle (US$), January’ 2020
Figure 20-31: Actimmune – Sales Value (US$/EUR Million), 2017 & 2018
Figure 20-32: Actimmune – Quarterly Sales Value (US$/EUR Million), Q1 – Q3, 2019
Figure 20-33: Ontack – Duration of Single Treatment Cycle & Full Treatment (Weeks), January’ 2020
Figure 20-34: Ontack – Average Minimum & Maximum Cost of Single Dose Administration (US$), January’ 2020
Figure 20-35: Ontack – Average Minimum & Maximum Cost of Single Treatment Cycle (US$), January’ 2020

Figure 21-1: Imlygic – US & European Patent Expiration Year
Figure 21-2: Imlygic – Price of 1 Million PUF/ml & 100 Million PUF/ml Injectable Suspension (US$), January’2020
Figure 21-3: Imlygic – Concentration of Dose for Initial Treatment Cycle & Subsequent Treatment Cycle (Million PUF/ml), January’2020
Figure 21-4: Imlygic – Average Price of Initial Treatment Cycle & Each Subsequent Treatment Cycle (US$), January’2020
Figure 21-5: Imlygic – Volume Administered by Size of Lesion (ml), January’2020

Figure 22-1: Kymriah – FDA approval Year by Cancer Type
Figure 22-2: Kymriah – Number of Patents in US, Europe & Japan
Figure 22-3: Kymriah – Cost of Advanced Lymphoma Treatment (US$ 000’), Janouary’2020
Figure 22-4: Kymriah – Cost of Acute Lymphoblastic Leukemia Treatment (US$ 000’), Janouary’2020
Figure 22-5: Kymriah - Sales Value (US$ Million), 2017 & 2018
Figure 22-6: Kymriah – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
Figure 22-7: Yescarta - FDA Approval & US Patent Expiration Year
Figure 22-8: Yescarta - Cost of Advanced Lymphoma Treatment (US$ 000’), Janouary’2020
Figure 22-9: Yescarta - Sales Value (US$ Million), 2017 & 2018
Figure 22-10: Yescarta – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019

Figure 28-1: Advaxis Clinical Pipeline
Figure 28-2: Celldex Therapeutics Clinical Pipeline
Figure 28-3: Expression Genetics Clinical Pipeline
Figure 28-4: Galena Biopharma Clinical Pipeline
Figure 28-5: ImmunoCellular Therapeutics Clinical Pipeline
Figure 28-6: ImmunoGen Clinical Pipeline
Figure 28-7: Inovio Pharmaceuticals Clinical Pipeline
Figure 28-8: NewLink Genetics Corporation Clinical Pipeline
Figure 28-9: Northwest Biotherapeutics Clinical Pipeline
Figure 28-10: Peregrine Pharmaceuticals Clinical Pipeline
Figure 28-11: Philogen Clinical Pipeline
Figure 28-12: Seattle Genetics Clinical Pipeline

 

List of Tables
Table 5-1: Different Monoclonal Antibodies Used in Cancer Immunotherapy
Table 7-1: Illustration of Some Important Checkpoint Inhibitors
Table 10-1: Few Important Immunocytokines under Clinical Development
Table 10-2: Some Pharmacologically Important Cytokines Used in Cancer Immunotherapies
Table 14-1: Few Commercially Important PD-1 Drugs